Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis

Inclusion Criteria:

• Diagnosis of cystic fibrosis confirmed
• Age ≥18 years
• 30% <FEV1 <70% predicted
• Presence of bronchial congestion reported by the patient or the investigator

Exclusion Criteria:

• Uncontrolled asthma
• Pneumothorax <6 weeks
• Recent severe hemoptysis <6 weeks
• Patient registered on the transplant list
• Exacerbation within 4 weeks (3 months if hospitalization) before screening
• Cardiovascular disorders, electrocardiogram (ECG) parameters or clinically significantrespiratory (non-cystic fibrosis) conditions
• Patients unable to perform measurements of ROF, spirometry, plethysmography.
• Any contraindication to manual or instrumental physiotherapy.
• Pregnancy, breastfeeding.
• Patient under tutorship or curatorship
• No affiliation to the French social security
• Patient using Simeox at home
• Patient under Trikafta for less than 6 weeks.
• Patient using Simeox more than twice a week during physiotherapy sessions, not wantinga washout period of 7 days before inclusion